Stacie B. Dusetzina, Ph.D.
Affiliations: | 2010 | Pharmaceutical Sciences | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Pharmacy, EpidemiologyGoogle:
"Stacie Dusetzina"Parents
Sign in to add mentor| Richard A. Hansen | grad student | 2010 | UNC Chapel Hill | |
| (Diagnosis and treatment of pediatric bipolar disorder in a commercially insured population.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dusetzina SB, Sarpatwari A, Carrier MA, et al. (2022) Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. Jama Internal Medicine. 181: 1605-1611 |
| Yeung K, Barthold D, Dusetzina SB, et al. (2020) Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps. The New England Journal of Medicine. 383: 558-566 |
| Dusetzina SB, Oberlander J. (2019) Advancing Legislation on Drug Pricing - Is There a Path Forward? The New England Journal of Medicine. 381: 2081-2084 |
| Mitchell AP, Kinlaw AC, Peacock-Hinton S, et al. (2019) Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. The Oncologist |
| Dusetzina SB, Keating NL, Huskamp HA. (2019) Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices. The New England Journal of Medicine |
| Dusetzina SB, Mello MM. (2018) Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues. The New England Journal of Medicine. 379: 2290-2293 |
| Knight TG, Deal AM, Dusetzina SB, et al. (2018) Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. Journal of Oncology Practice. JOP1800120 |
| Olszewski AJ, Dusetzina SB, Trivedi AN, et al. (2018) Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018778894 |
| Rotenstein LS, Dusetzina SB, Keating NL. (2018) Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy. 24: 494-502 |
| Smitherman AB, Mohabir D, Wilkins TM, et al. (2018) Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. The Journal of Pediatrics |